| 1ZKL | A: | MULTIPLE DETERMINANTS FOR INHIBITOR SELECTIVITY OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASES |
| 2OUN | A:; B: | CRYSTAL STRUCTURE OF PDE10A2 IN COMPLEX WITH AMP |
| 2OUP | A:; B: | CRYSTAL STRUCTURE OF PDE10A |
| 2OUQ | A:; B: | CRYSTAL STRUCTURE OF PDE10A2 IN COMPLEX WITH GMP |
| 2OUR | A:; B: | CRYSTAL STRUCTURE OF PDE10A2 MUTANT D674A IN COMPLEX WITH CAMP |
| 2OUS | A:; B: | CRYSTAL STRUCTURE OF PDE10A2 MUTANT D674A |
| 2OUU | A:; B: | CRYSTAL STRUCTURE OF PDE10A2 MUTANT D674A IN COMPLEX WITH CGMP |
| 2OUV | A:; B: | CRYSTAL STRUCTURE OF PDE10A2 MUTANT OF D564N |
| 2OUY | A:; B: | CRYSTAL STRUCTURE OF PDE10A2 MUTANT D564A IN COMPLEX WITH CAMP. |
| 2WEY | A:; B: | HUMAN PDE-PAPAVERINE COMPLEX OBTAINED BY LIGAND SOAKING OF CROSS-LINKED PROTEIN CRYSTALS |
| 2Y0J | A:; B: | TRIAZOLOQUINAZOLINES AS A NOVEL CLASS OF PHOSPHODIESTERASE 10A (PDE10A) INHIBITORS, PART 2, LEAD-OPTIMISATION. |
| 3ECM | A: | CRYSTAL STRUCTURE OF THE UNLIGANDED PDE8A CATALYTIC DOMAIN |
| 3ECN | A:; B: | CRYSTAL STRUCTURE OF PDE8A CATALYTIC DOMAIN IN COMPLEX WITH IBMX |
| 3G3N | A: | PDE7A CATALYTIC DOMAIN IN COMPLEX WITH 3-(2,6-DIFLUOROPHENYL)-2-(METHYLTHIO)QUINAZOLIN-4(3H)-ONE |
| 3SN7 | A:; B: | HIGHLY POTENT, SELECTIVE, AND ORALLY ACTIVE PHOSPHODIESTARASE 10A INHIBITORS |
| 3SNI | A:; B: | HIGHLY POTENT, SELECTIVE, AND ORALLY ACTIVE PHOSPHODIESTARASE 10A INHIBITORS |
| 3SNL | A:; B: | HIGHLY POTENT, SELECTIVE, AND ORALLY ACTIVE PHOSPHODIESTARASE 10A INHIBITORS |
| 3UI7 | A:; B: | DISCOVERY OF ORALLY ACTIVE PYRAZOLOQUINOLINE AS A POTENT PDE10 INHIBITOR FOR THE MANAGEMENT OF SCHIZOPHRENIA |
| 3UUO | A:; B: | THE DISCOVERY OF POTENT, SELECTIVITY, AND ORALLY BIOAVAILABLE PYROZOLOQUINOLINES AS PDE10 INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA |
| 3WI2 | A:; B: | CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH INHIBITOR |
| 4AEL | A:; B: | PDE10A IN COMPLEX WITH THE INHIBITOR AZ5 |
| 4AJD | A:; D: | IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF PDE10 FRAGMENT INHIBITORS |
| 4AJF | A:; D: | IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF PDE10 FRAGMENT INHIBITORS |
| 4AJG | A:; D: | IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF PDE10 FRAGMENT INHIBITORS |
| 4AJM | A:; D: | DEVELOPMENT OF A PLATE-BASED OPTICAL BIOSENSOR METHODOLOGY TO IDENTIFY PDE10 FRAGMENT INHIBITORS |
| 4BBX | B: | DISCOVERY OF A POTENT, SELECTIVE AND ORALLY ACTIVE PDE10A INHIBITOR FOR THE TREATMENT OF SCHIZOPHRENIA |
| 4DDL | A:; B: | PDE10A CRYSTAL STRUCTURE COMPLEXED WITH NOVEL INHIBITOR |
| 4DFF | A:; B: | THE SAR DEVELOPMENT OF DIHYDROIMIDAZOISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA |
| 4FCB | A:; B: | POTENT AND SELECTIVE PHOSPHODIESTERASE 10A INHIBITORS |
| 4FCD | A:; B: | POTENT AND SELECTIVE PHOSPHODIESTERASE 10A INHIBITORS |
| 4HEU | A:; B: | CRYSTAL STRUCTURE OF PDE10A WITH A BIARYL ETHER INHIBITOR ((1-(3-(4-((1H-BENZO[D]IMIDAZOL-2-YL)AMINO)PHENOXY)PYRIDIN-2-YL)PIPERIDIN-4-YL)METHANOL) |
| 4HF4 | A:; B: | CRYSTAL STRUCTURE OF PDE10A WITH A BIARYL ETHER INHIBITOR (1-(1-(3-(4-(BENZO[D]THIAZOL-2-YLAMINO)PHENOXY)PYRAZIN-2-YL)PIPERIDIN-4-YL) ETHANOL) |
| 4LKQ | A:; B: | CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT017 |
| 4LLJ | A:; B: | CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT214 |
| 4LLK | A:; B: | CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT217 |
| 4LLP | A:; B: | CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT401 |
| 4LLX | A:; B: | CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT434 |
| 4LM0 | A:; B: | CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT448 |
| 4LM1 | A:; B: | CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT450 |
| 4LM2 | A:; B: | CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT462 |
| 4LM3 | A:; B: | CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT464 |
| 4LM4 | A:; B: | CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT902 |
| 4MUW | A:; B: | CRYSTAL STRUCTURE OF PDE10A WITH NOVEL KETO-BENZIMIDAZOLE INHIBITOR |
| 4MVH | A:; B: | CRYSTAL STRUCTURE OF PDE10A WITH NOVEL KETO-BENZIMIDAZOLE INHIBITOR |
)
)